Navigation Links
Blood Clotting Disorders Linked To Three Proteins

Barry Coller, David Rockefeller Professor and the university’s physician-in-chief, says that focusing on a receptor on the surface of blood platelets //could offer new insights insight into potential causes and treatments for certain heart diseases. Platelets are the blood cells that cause clotting and play an important role in the development of many heart diseases.

Coller has been working on Glanzmann thrombasthenia, a rare disorder, in which platelets lack one of two proteins. The two protiens, áIIb and a3, are involved in collecting blood cells for coagulation. By analyzing patients with this disorder, Coller was able to arrive at a new therapy, which could give hope to heart attack and stroke patients. The findings are published in the April 1 issue of Blood. Coller and Beau Mitchell, a research associate in Coller’s lab along with colleagues at the Mount Sinai School of Medicine found that the production of the protein was controlled by a third molecule called calnexin, which plays an important role in protein folding. These receptors could also play a role in cancer formation and metastases. But further research is needed. “Insights into rare diseases allow us to study and devise strategies for common diseases," Coller said
'"/>




Page: 1

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Reportlinker Adds Training Manikins - Global Trends 2Reportlinker Adds Training Manikins - Global Trends 3Reportlinker Adds Training Manikins - Global Trends 4Reportlinker Adds Training Manikins - Global Trends 5Accenx Information Exchange Platform Live With BayCares RxHistory Goal to Reach 8 200 Users 52746 1Accenx Information Exchange Platform Live With BayCares RxHistory Goal to Reach 8 200 Users 52746 2Independent Study Confirms Superior Properties of ZPC 28TM 29 Enhanced Calcium Composite Bone Grafts 13202 1Independent Study Confirms Superior Properties of ZPC 28TM 29 Enhanced Calcium Composite Bone Grafts 13202 2GenVec Expands Contract Supporting Malaria Vaccine Program 13200 1GenVec Expands Contract Supporting Malaria Vaccine Program 13200 2GenVec Expands Contract Supporting Malaria Vaccine Program 13200 3